This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldberg, R. M. Articles by O’Connell, M. J. Search for Related Content PubMed PubMed Citation Articles by Goldberg, R. M. Articles by O’Connell, M. J. Social Bookmarking                            What's this?

Early Detection of Toxicity and Adjustment of Ongoing Clinical Trials: The History and Performance of the North Central Cancer Treatment Group’s Real-Time Toxicity Monitoring Program

From the Divisions of Medical Oncology and Biostatistics, Mayo Clinic, Rochester, and The Duluth Clinic, Ltd, Duluth, MN; and Iowa Oncology Research Association, Des Moines, IA.

Address reprint requests to Richard M. Goldberg, MD, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; email: goldberg.richard{at}mayo.edu

ABSTRACT: Prospective clinical trials are the gold standard for evidence-based methodology used to support changes in the practice of medicine. Clinical researchers, regulatory agencies, payers, and the public embrace the conduct of phase I, II, and III clinical trials as integral to improving patient care. The National Cancer Institute (NCI) funds a number of cooperative oncology groups to conduct such clinical trials in the United States. In order to protect enrolling patients, the NCI requires expedited reporting to allow rapid identification of severe side effects on NCI-sponsored clinical trials. However, chemotherapy drugs frequently cause predictable side effects, the rapid reporting of which would potentially overwhelm the system. This article describes the development and documents the performance of a real-time toxicity reporting system implemented by the North Central Cancer Treatment Group. The goal of this system is to supplement the currently required NCI adverse event monitoring procedures and to permit study teams to identify the need to modify ongoing clinical trials. The system has proven its value in the monitoring of phase II and III trials, including trial N9741, a three-arm, phase III, advanced colorectal cancer chemotherapy study exploring combinations of irinotecan, oxaliplatin, and fluorouracil. We believe the methods described present opportunities for improving patient safety in clinical research.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. M. Goldberg, D. J. Sargent, R. F. Morton, E. Green, H. K. Sanoff, H. McLeod, and J. Buckner NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial Oncologist, October 1, 2009; 14(10): 970 - 978. [Abstract] [Full Text] [PDF]

				E. Basch, D. Artz, A. Iasonos, J. Speakman, K. Shannon, K. Lin, C. Pun, H. Yong, P. Fearn, A. Barz, et al. Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities J. Am. Med. Inform. Assoc., May 1, 2007; 14(3): 264 - 268. [Abstract] [Full Text] [PDF]

				R. M. Goldberg Therapy for Metastatic Colorectal Cancer Oncologist, October 1, 2006; 11(9): 981 - 987. [Abstract] [Full Text] [PDF]

				S. J. Anderson Some Thoughts on the Reporting of Adverse Events in Phase II Cancer Clinical Trials J. Clin. Oncol., August 20, 2006; 24(24): 3821 - 3822. [Full Text] [PDF]

				O. Scharf and A. D. Colevas Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials J. Clin. Oncol., August 20, 2006; 24(24): 3933 - 3938. [Abstract] [Full Text] [PDF]

				N. J. Meropol Turning Point for Colorectal Cancer Clinical Trials J. Clin. Oncol., July 20, 2006; 24(21): 3322 - 3324. [Full Text] [PDF]

				R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. Alberts Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial J. Clin. Oncol., July 20, 2006; 24(21): 3347 - 3353. [Abstract] [Full Text] [PDF]

				M. R. Mahoney, D. J. Sargent, M. J. O'Connell, R. M. Goldberg, P. Schaefer, and J. C. Buckner Dealing With a Deluge of Data: An Assessment of Adverse Event Data on North Central Cancer Treatment Group Trials J. Clin. Oncol., December 20, 2005; 23(36): 9275 - 9281. [Abstract] [Full Text] [PDF]

				E. Basch, D. Artz, D. Dulko, K. Scher, P. Sabbatini, M. Hensley, N. Mitra, J. Speakman, M. McCabe, and D. Schrag Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy J. Clin. Oncol., May 20, 2005; 23(15): 3552 - 3561. [Abstract] [Full Text] [PDF]